Skip to main content

Practice Management

Practice Management

Cost Management through Care Management, Part 2: The Importance of Managing Specialty Drug Utilization in the Medical Benefit

Michael T. Einodshofer, RPh, MBA, Lars N. Duren, BCNSP, PharmD

Practice Management

Medical Care Costs and Hospitalization in Patients with Bipolar Disorder Treated with Atypical Antipsychotics

Joette Gdovin Bergeson, PhD, MPA, Iftekhar Kalsekar, PhD, Yonghua Jing, PhD, Min You, MS, Robert A. Forbes, PhD, Tony Hebden, PhD

Stakeholder Perspective

The Potential Value of Benefit Design and Medication Selection for a Total-Cost-of-Care Strategy in Bipolar Disease

by Jeff Januska, PharmD

Practice Management

"Hidden” Value: How Indirect Benefits of Health Information Exchange Further Promote Sustainability

Albert Tzeel, MD, MHSA, CPE, FAAPL, Victor Lawnicki, PhD, Kim R. Pemble, MS

Stakeholder Perspective

Significant Potential for Health Information Exchange in Enhancing Quality of Care and Reducing Hospital Admissions in the United States

by Jack E. Fincham, PhD, RPh

Practice Management

Curbing the Costly Trend: Exploring the Need for a Progressive Approach to the Management of Specialty Pharmaceuticals Under the Medical Benefit

Michael S. Jacobs, RPh, Kjel A. Johnson, PharmD, BcPS, FccP, FAMcP

Stakeholder Perspective

Managing Medical Benefit Drugs Under Specialty Pharmacy: The Next Critical Challenge for Managed Care

by James T. Kenney, RPh, MBA

Practice Management

Cost Management through Care Management: A Perspective on Choosing the Right Specialty Pharmacy Partner, PART 1

Michael Einodshofer, RPh, MBA, Stephen Kansler

Practice Management

Emerging Trends in Cancer Care: Health Plans’ and Pharmacy Benefit Managers’ Perspectives on Changing Care Models

Rhonda Greenapple, MSPH, Gary M. Owens, MD

Practice Management

Recent Developments, Utilization, and Spending Trends for Pompe Disease Therapies

Jing Guo, BPharm, Christina M.L. Kelton, PhD, Jeff J. Guo, PhD

Stakeholder Perspective

Beyond “Patient Amusement”: New Treatments and Genetic Disease

by Albert Tzeel, MD, MHSA, CPE, FAAPL

Practice Management

Utilization of Anticoagulation Therapy in Medicare Patients with Nonvalvular Atrial Fibrillation

Delete Delete, Jonah Broulette, Bruce S. Pyenson, FSA, MAAA, Kosuke Iwasaki, FIAJ, MAAA, Winghan Jacqueline Kwong, PharmD, PhD, Michael F. Murphy, MD, PhD

Stakeholder Perspective

Warfarin Utilization in Medicare Patients with Nonvalvular Atrial Fibrillation: Sentinel Data from an Administrative Claims Database

Practice Management

Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers

Rhonda Greenapple, MSPH

Stakeholder Perspective

Biologic Therapies for Rheumatoid Arthritis: It's All about Value

by Albert Tzeel, MD, MHSA, CPE, FAAPL

Practice Management

Impact of the Removal of the Monthly Liver Function Test Requirement for Ambrisentan

Louise A. Durst, RN, John Carlsen, MHA, Megan Kuchinski, MPH, Lauren Harner, JD, Daniel Neves, BA, Stephanie J. Harris, RN, BSN, Glenna L. Traiger, RN, MSN, CNS-BC

Stakeholder Perspective

The Challenges of Pulmonary Arterial Hypertension Management: Potential Benefits of Removing Monthly Testing

by James T. Kenney, RPh, MBA

Page 20 of 32
Results 191 - 200 of 318